Bracket Releases Rater Station 4.0 eCOA Solution
The Rater Station℠ platform has been used extensively in Central Nervous System clinical trials, and version 4.0 is currently being used in two clinical trials that are actively recruiting.
Bracket, a clinical trial specialty services provider, has released version 4.0 of Rater Stationâ , its Electronic Clinical Outcomes Assessment (eCOA) tool. The Rater Stationâ platform has been used extensively in Central Nervous System clinical trials, and version 4.0 is currently being used in two clinical trials that are actively recruiting.
The new version includes the following features:
- Persistent Auto-Save, loss of power, user error, or system malfunction will never mean lost data.
- Advanced authentication and user management features, allowing study sponsors more control of which site personnel can access data.
- Improved Question Library, allows for advanced customization for each scale and questionnaire programmed into the platform.
- Improved clinical edit checks, designed to reduce errors and minimize data corrections.
- New workflow that streamlines subject visits for study personnel.
Read the full release.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
